华创医药投资观点&研究专题周周谈 · 第164期 海外CXO 2025财报总结&2026年展望 www.hczq.com 证券研究报告 | 医药生物 | 2026年2月28日 本周专题联系人：王宏雨 | 华创医药团队： | | | | --- | --- | --- | | 首席分析师郑辰 | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | 联席首席分析师刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 高级分析师王宏雨 | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 高级分析师朱珂琛 | 执业编号：S0360524070007 | 邮箱：zhukechen@hcyjs.com | | 分析师陈俊威 | 执 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 97.65 [1][5] Core Insights - The company, Nanwei Medical, is a leading domestic player in endoscopic medical consumables, with significant growth in international markets, particularly in developed countries. From 2014 to 2024, overseas revenue is expected to grow 12.6 times, with nearly 60% of revenue coming from international markets in 9M25. The company is well-positioned to benefit from a stable domestic policy environment regarding centralized procurement [1][16] - The report highlights the company's strong global expansion capabilities, with a compound annual growth rate (CAGR) of 30% in overseas revenue from 2013 to 2024. The direct sales model has significantly increased its contribution to revenue, indicating a robust international market presence [2][4] Summary by Sections Overseas Market Performance - The company has achieved a CAGR of 30% in overseas revenue from 2013 to 2024, with 9M25 overseas revenue reaching RMB 1.4 billion, a year-on-year increase of 42%. The Americas, EMEA, and Asia-Pacific regions have shown growth rates of 20%, 73%, and 32% respectively, with overseas revenue accounting for 59% of total revenue [2][16] - The global endoscopic market is projected to grow from approximately USD 6 billion in 2023 to USD 7.4 billion by 2026, with the company currently holding less than 6% market share, indicating significant growth potential [2][33] Domestic Market Dynamics - The impact of centralized procurement on domestic revenue is expected to diminish, with the company winning bids in key regions without further price declines. The government has emphasized quality over price in procurement policies, which stabilizes expectations for future revenue [3][18] - Domestic revenue for 9M25 was RMB 980 million, reflecting a year-on-year decrease of 4.7% due to procurement pressures, but the company anticipates a gradual recovery as overseas revenue continues to grow [3][24] Differentiation from Market Views - The report argues that concerns regarding the impact of centralized procurement are manageable and decreasing. The company’s overseas revenue share is expected to continue rising, while the share of non-procurement products in domestic revenue is likely to decline [4][19] - The market has not fully recognized the company's exceptional global business capabilities, with overseas revenue growth and contribution metrics indicating that Nanwei Medical is among the top tier of domestic medical device companies [4][19] Financial Projections - The company forecasts net profits of RMB 600 million, RMB 710 million, and RMB 840 million for 2025, 2026, and 2027 respectively, with corresponding earnings per share (EPS) of RMB 3.22, RMB 3.76, and RMB 4.49. The valuation is set at 26x PE for 2026, leading to a target price of RMB 97.65 [5][9]

Summary of the Conference Call for Peijia Medical Company and Industry Overview - **Company**: Peijia Medical - **Industry**: Medical Devices, specifically focusing on TAVR (Transcatheter Aortic Valve Replacement) and neurointerventional products Key Points and Arguments Industry Updates 1. The TAVR industry is projected to grow at a rate of 7-8% by 2025, which is slower than previous expectations of around 10% [3] 2. The overall surgical volume in January showed positive growth, indicating a potential recovery in the TAVR market [3] 3. Price adjustments initiated by the healthcare authorities have led to a more favorable pricing structure for innovative products, allowing for higher price points for new offerings [4][11] Company Performance 1. Peijia Medical reported a surgical volume of nearly 3,900 TAVR procedures, with a growth rate of approximately 15%, which is double the industry average [7] 2. The company’s new 2.5 generation valve has gained significant market acceptance, contributing to a 5% increase in implant volume despite being priced at a premium [7] 3. The company expects to achieve a break-even point in profitability by 2026, driven by the performance of its neurointerventional products and the anticipated growth in TAVR procedures [21][56] Product Developments 1. The company successfully launched its new aortic valve product, which is expected to drive significant revenue growth in 2026 [6] 2. Peijia Medical has submitted registration applications for its mitral valve product in Europe, with expectations for approval by the end of the year [6] 3. The company anticipates that the new mitral valve product will generate substantial revenue, with an estimated 1,000 procedures expected in the first half of 2026 [25] Pricing and Market Strategy 1. The pricing strategy for the new mitral valve product aims to position it at the highest price point among domestic competitors, reflecting its innovative features [24] 2. The company has adopted a more conservative approach to subsidies, focusing on financial profitability rather than aggressive market share expansion [32] 3. The recent price adjustments are expected to enhance patient affordability and increase surgical volumes, despite concerns about reimbursement from healthcare authorities [35][41] Competitive Landscape 1. New entrants in the market are expected to increase competition, but Peijia Medical believes that these companies will require time to establish themselves [50] 2. The company maintains a strong market position, with a market share increase to approximately 26.5%, reflecting a growth of 1-2 percentage points from the previous year [10] Other Important Insights 1. The company is optimistic about the long-term growth potential of the TAVR market, despite current challenges [3] 2. Peijia Medical's strategy emphasizes continuous innovation and product differentiation to maintain a competitive edge in the market [52] 3. The management is focused on balancing immediate profitability with long-term growth objectives, ensuring that investments in R&D continue to drive future success [56]

Group 1 - The core viewpoint of the news highlights the positive performance of the Chinese pharmaceutical and medical device innovation index, with significant gains in specific stocks and a new development plan for traditional Chinese medicine [1] - The China Securities Regulatory Commission and eight other departments have issued a plan to promote the high-quality development of traditional Chinese medicine, aiming to approve a batch of innovative traditional Chinese medicines and cultivate ten major traditional Chinese medicine products by 2030 [1] - The overall funding congestion in the innovative drug sector has slightly decreased compared to Q2, with some funds temporarily withdrawing from innovative drugs, while the medical device sector remains stable and is expected to attract more investment [1] Group 2 - The China Medical and Medical Device Innovation Index (931484) includes 30 listed companies with good profitability and growth potential, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index account for 63.9% of the total index, including companies like WuXi AppTec, Mindray Medical, and Hengrui Medicine [2]

Core Viewpoint - The domestic high-value medical consumables market is undergoing significant changes due to centralized procurement, with domestic companies expected to capture approximately 70% of the mainstream market in the coming years [1][2]. Group 1: Market Dynamics - The sixth batch of national centralized procurement for high-value medical consumables was announced, with 202 companies and 440 products winning bids, indicating a shift towards domestic brands [1]. - Since the implementation of centralized procurement in 2020, the market share of imported brands, which previously dominated over 90%, has been continuously eroded, leading to significant price reductions in products like coronary stents and drug-coated balloons [1][2]. - The average price of joint bone cement dropped by 83.13% due to centralized procurement, significantly reducing the financial burden on patients [2]. Group 2: Competitive Landscape - Domestic companies face a more severe challenge in the medical device sector compared to pharmaceuticals, as the technological gap between domestic products and imported brands is more pronounced [2]. - The centralized procurement model has created a dual-edged sword for domestic companies, allowing them to gain market access while also compressing profit margins due to intense price competition [2][3]. Group 3: Company Performance - Guichuang Tongqiao has actively embraced centralized procurement, resulting in a compound annual growth rate of 50-60% in performance after its products were included in procurement lists [3]. - The company has successfully maintained a gross margin of 71.6% in 2024, only slightly down from 2023, indicating resilience against price pressures [4]. Group 4: Future Outlook - The market for neuro-interventional consumables is expected to slow down after rapid growth, while the peripheral vascular business is projected to maintain a steady growth rate of around 40% [5]. - The company recognizes the need to enhance product quality and build trust among clinicians to facilitate the adoption of domestic brands [5]. Group 5: International Expansion - The international market for medical devices is significantly larger than the domestic market, making global expansion a necessity for companies like Guichuang Tongqiao [6][8]. - The company has entered into an agreement to acquire a stake in the German medical technology company Optimed, aiming to leverage its established R&D and commercialization platform in Europe [8][9]. - Innovation is deemed essential for gaining recognition in mainstream international markets, with the company focusing on both mergers and innovative product development to enhance its global presence [9].

Core Viewpoint - The recent announcement of the sixth batch of high-value medical consumables procurement in China indicates a significant shift towards domestic brands, with industry experts predicting that leading domestic companies will capture approximately 70% of the mainstream market [2]. Group 1: Market Dynamics - Since the implementation of high-value consumables procurement in 2020, the process of domestic substitution has accelerated, with imported brands previously dominating over 90% of the market share being increasingly challenged [2]. - The average price of coronary stents has dropped to around 1,000 yuan, and drug-coated balloon prices have also fallen to similar levels, significantly reducing surgical costs [2]. - By 2024, the market share of domestic neurointerventional products has risen to 26%, reshaping the competitive landscape [5]. Group 2: Company Performance - Guichuang Tongqiao has successfully embraced procurement, resulting in a compound annual growth rate of 56% in performance after its products were included in the procurement list [4]. - The company has maintained a gross margin of 71.6% in 2024, only slightly down by 1.3 percentage points from 2023, indicating resilience against price pressures [5]. - Guichuang Tongqiao's products have achieved significant market penetration, with certain products like the capture device leading in market share in Hebei [5]. Group 3: Challenges and Opportunities - Despite the rapid growth of domestic medical devices, there remains a notable gap in innovation capabilities compared to foreign counterparts, with many domestic products lacking substantial intellectual property [2][3]. - The procurement model has created a dual-edged sword for domestic companies, providing opportunities for market access while also compressing profit margins due to intense price competition [3]. - The company recognizes the need to build trust with clinicians, who are often accustomed to using imported products, emphasizing the importance of product quality and user education [6]. Group 4: International Expansion - The international market presents a significant opportunity for domestic medical device companies, with Guichuang Tongqiao already entering over 80 countries and regions [9]. - The company plans to expand its global footprint through acquisitions, such as the agreement with Optimed Medizinische Instrumente GmbH, to leverage established R&D and commercialization platforms in Europe [9]. - Innovation remains crucial for gaining recognition in mainstream markets, with the company acknowledging the longer timelines required for medical device innovation compared to pharmaceuticals [10].

Market Overview - The Shanghai Composite Index rose by 1.38% to close at 4023.42 points, with a daily high of 4025.26 points [1] - The Shenzhen Component Index increased by 2.24% to close at 13828.63 points, reaching a high of 13828.97 points [1] - The ChiNext Index saw a rise of 2.85%, closing at 3294.55 points, with a peak of 3295.29 points [1] ETF Market Performance - The median return of stock ETFs was 2.12%, with the highest return from the Southern CSI Star Market 50 ETF at 4.85% [2] - The highest performing industry index ETF was the China Securities All Index Medical Devices ETF, yielding 6.95% [2] - The highest return among thematic index ETFs was from the Ping An CSI Hong Kong-Shanghai Online Consumption Theme ETF at 6.94% [2] ETF Gains and Losses - The top three ETFs by gain were: - China Securities All Index Medical Devices ETF (6.95%) - Ping An CSI Hong Kong-Shanghai Online Consumption Theme ETF (6.94%) - Yongying CSI All Index Medical Devices ETF (6.37%) [5] - The top three ETFs by loss were: - China Securities Tourism Theme ETF (-1.35%) - Fortune CSI Tourism Theme ETF (-1.11%) - Penghua CSI 800 Free Cash Flow ETF (-0.78%) [6] ETF Fund Flows - The top three ETFs by fund inflow were: - Southern CSI 500 ETF (28.42 billion) - Huatai-PB CSI 300 ETF (11.02 billion) - Southern CSI Shenwan Nonferrous Metals ETF (9.15 billion) [8] - The top three ETFs by fund outflow were: - Southern CSI A500 ETF (12.88 billion) - Huaan ChiNext 50 ETF (9.97 billion) - Huatai-PB CSI A500 ETF (8.82 billion) [9] ETF Margin Trading Overview - The highest margin buy amounts were for: - Huatai-PB CSI 300 ETF (0.776 billion) - China Securities Star Market 50 ETF (0.682 billion) - Guotai Junan CSI All Index Securities Company ETF (0.47 billion) [11] - The highest margin sell amounts were for: - Huatai-PB CSI 300 ETF (63.87 million) - China Securities Star 50 ETF (34.55 million) - Southern CSI 500 ETF (23.85 million) [12] Institutional Insights - Century Securities suggests focusing on the transformation progress of leading companies in the medical device sector, which has gained market share post centralized procurement [13] - Guojin Securities emphasizes investment strategies in the medical device sector should focus on overseas expansion and innovation, as these areas provide additional growth opportunities and support profit margins during price declines in traditional businesses [14]

Group 1 - The medical device sector experienced a strong start in 2026, with multiple stocks hitting the daily limit up, including Mindray Medical, United Imaging, and South Micro Medical, among others [1] - The Medical Device Index ETF (159898) saw a significant increase of over 5%, with a net subscription of 27 million units and a net inflow of over 15 million yuan [1][2] - Recent government initiatives, such as the National Medical Products Administration's (NMPA) establishment of a priority approval list for high-end medical devices, aim to accelerate the market entry of innovative products [3] Group 2 - The medical device sector has gained attention in specific areas like brain-computer interfaces, indicating potential for continued performance [3] - The NMPA's new regulations on export sales certificates for medical devices will facilitate better pricing strategies for companies in the global market [3] - Century Securities suggests that domestic medical device manufacturers have gained significant market share post-consolidated procurement, benefiting from scale effects and export policies [4] Group 3 - The Medical Device Index ETF (159898) tracks the CSI All-Index Medical Devices, with major holdings in leading companies like Mindray Medical and United Imaging, reflecting a strong representation of the A-share medical device sector [4]

Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has received acceptance for its IPO on the ChiNext board, focusing on high-performance vascular interventional medical devices and leading in the domestic market for vascular balloon catheters [1] Group 1: IPO and Fundraising - The company aims to raise 1.7 billion yuan through its IPO, which will be used for the global headquarters project, production base upgrades, R&D projects, marketing network construction, and working capital [1] - The total investment for the projects funded by the IPO is approximately 18.15 billion yuan, with specific allocations for each project detailed in the financial table [2] Group 2: Financial Performance - The company reported revenues of 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan over the reporting periods, with net profits of -30.26 million yuan, 28.50 million yuan, 77.44 million yuan, and 35.80 million yuan, indicating a rapid growth trend [3] - The revenue from the distribution model accounted for 89.15%, 88.38%, 90.60%, and 88.61% of total revenue during the reporting periods, highlighting the reliance on distributors [4] Group 3: R&D and Expenses - R&D expenditures for the years 2022, 2023, and 2024 were 55.76 million yuan, 60.47 million yuan, and 76.53 million yuan, totaling 193 million yuan, with R&D expenses as a percentage of revenue decreasing over time [6] - The company’s sales expenses were 41.78 million yuan, 62.80 million yuan, 86.69 million yuan, and 53.07 million yuan, with a decreasing trend in sales expenses as a percentage of revenue [8] Group 4: Market Challenges and Risks - The company faces potential challenges in international expansion due to complex trade environments and increasing policy uncertainties, particularly in Europe and Asia-Pacific regions [4] - The reliance on distributors poses risks to brand reputation and operational stability, as any misconduct by distributors could adversely affect the company [4] Group 5: Shareholder Agreements - The actual controller and major shareholders are subject to a buyback agreement, which may be triggered if the company fails to meet certain performance targets post-IPO [11] - If the IPO is unsuccessful, the buyback obligations will be reinstated, potentially requiring the actual controller to repurchase shares from investors [12]

Summary of the Conference Call for Weili Medical Industry Overview - The Chinese medical device market has experienced an overall negative growth in the first three quarters of 2025 due to the impacts of centralized procurement, DRG policies, and anti-corruption measures [2][3] - Despite the challenges, companies with competitive advantages in international markets or those at the forefront of technology still present investment potential [2] - The global medical device market has maintained steady growth, with an annual growth rate of approximately 5% to 10%, and a market size exceeding one trillion USD [3] Company Performance - Weili Medical has a balanced domestic and international presence, with a reasonable valuation and stable performance. The overall revenue growth is expected to be around 15% by 2025, with overseas revenue accounting for approximately 53% [2][6] - Domestic market growth is slowing due to centralized procurement but has returned to positive growth [2][6] - The company’s product portfolio includes anesthesia series, catheter series, urology products, nursing supplies, and blood dialysis products, with urology and anesthesia each accounting for about 30% of sales [6][7] Product Insights - The urology segment has a high gross margin of 75%, while the anesthesia series has seen negative growth due to a decline in surgical volumes [7] - Blood dialysis equipment sales increased by 50% despite a 30% to 40% drop in factory prices, indicating a shift towards domestic brands [8] - New products such as silicone catheters and temperature-measuring catheters have performed well in overseas markets, with silicone catheters achieving a gross margin of 50% and a growth rate of 30% [9] Strategic Developments - Weili Medical plans to establish factories in Mexico and Indonesia to mitigate tariff risks, with the Indonesian factory expected to start shipping by the end of 2026 [4][12] - The company anticipates a 20% growth in overseas business next year, driven by new CDMO projects and local operations [13] Market Dynamics - The competitive landscape in the medical device sector has shifted, with domestic brands gaining market share as imported products decline [8] - The company is transitioning from low-quality consumables to medium and high-quality consumables, with high-quality consumables currently accounting for 20% to 25% of sales and growing at 25% annually [10] Risks and Challenges - The centralized procurement policy poses risks, particularly for urology products, which may face significant price reductions if the procurement process is delayed [14] - The expected price drop for terminal prices could be around 50%, with factory prices potentially decreasing by 30%, which may negatively impact gross margins [14] Conclusion - Weili Medical is positioned well within the medical device industry, with a strong focus on international expansion and product innovation. However, it must navigate the challenges posed by domestic policies and market dynamics to sustain its growth trajectory.